Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Metcovid
  NCT04343729		 RCTmethylprednisoloneplaceboCOVID 19 hospitalizedsome concern
209/207 inconclusive
  • inconclusive 8 % decrease in deaths,death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
Tang X
  NCT04273321		 RCTmethylprednisoloneplaceboCOVID 19 hospitalizedsome concern
43/43 suggested
  • inconclusive 0 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 78 % increase in viral clearance ,viral clearance (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias

COVID-19 severe or critically meta-analysis

Munch (COVID-STEROID)
  NCT04348305		 RCTHydrocortisoneplaceboCOVID-19 severe or criticallylow
16/14 no results
    CAPE-COVID
          NCT02517489    		 RCTHydrocortisoneplaceboCOVID-19 severe or criticallylow
    		76/73 inconclusive
    • inconclusive 29 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

     

    - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons